Replies to post #19374 on Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

No, same old patent. The current (only remaining) patent expires in July 2014. The new patent application is here:

http://portal.uspto.gov/pair/PublicPair

search for Publication number 20100248269

It was filed in 2009, rejected in 2012, refiled at the last minute in 2013, and is now sitting in the queue at the USPTO with no activity in the past year. Same examiner who rejected the original app is reviewing the "new" app.

There is a clone of this app sitting in the World (WIPO) system. That WIPO app was filed in 2009 at the same time as the original US Patent app. This WIPO app has had no activity for years.

http://patentscope.wipo.int/search/en/detail.jsf?docId=US43372568&recNum=4&office=&queryString=fibrinogen+cancer+degradation+detection+monitoring&prevFilter=&sortOption=Relevance&maxRec=11890

Radient let the European patent application expire. I think UNI was supposed to keep paying the annual fees for that, but neglected to do so.